Loading clinical trials...
Loading clinical trials...
Open Multicentre, Phase IV Study to Evaluate Efficacy and Safety of Pegylated Interferon Alpha-2a (40 KD) Plus Ribavirin for Chronic Hepatitis C With Normal Transaminases in Human Immunodeficiency Virus-infected Patients
Conditions
Interventions
Peginterferon alfa-2a + ribavirin in normal ALT
Peginterferon alfa-2a + ribavirin in elevated ALT
Locations
18
Spain
Hospital de Txagorritxu
Vitoria-Gasteiz, Alava, Spain
Hospital del Mar
Barcelona, Barcelona, Spain
Hospital Santa Creu i Sant Pau
Barcelona, Barcelona, Spain
Hospital Clinic
Barcelona, Barcelona, Spain
Consorci Sanitari Integral
Hospitalet, Barcelona, Spain
Hospital Universitari of Bellvitge
Hospitalet, Barcelona, Spain
Start Date
September 1, 2006
Primary Completion Date
May 1, 2011
Completion Date
June 1, 2011
Last Updated
September 13, 2012
NCT00199719
NCT06922643
NCT03612973
NCT01866930
NCT05895448
NCT02219490
Lead Sponsor
Miguel Santin
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions